Aldeyra shares spi­ral af­ter a late-stage fail­ure in dry eye dis­ease — but that won't stop its pur­suit of an NDA

Aldeyra Ther­a­peu­tics’ shares tanked in pre­mar­ket trad­ing af­ter the com­pa­ny ad­mit­ted its dry eye can­di­date re­prox­alap missed the pri­ma­ry end­point in a topline Phase III read­out — but who needs the pri­ma­ry?

De­spite the late-stage fail­ure, Aldeyra is charg­ing ahead with an­oth­er Phase III tri­al, and CEO Todd Brady is con­fi­dent a sec­ondary end­point will lead the can­di­date to suc­cess.

“We con­tin­ue to ad­vance re­prox­alap to­ward NDA sub­mis­sion as we fo­cus on the com­ple­tion of TRAN­QUIL­I­TY-2 and en­roll­ment in the 12-month safe­ty tri­al,” he said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER